Donald Bellgrau

Fondatore presso ApopLogic Pharmaceuticals, Inc.

Consumer Services

Health Technology

Posizioni attive di Donald Bellgrau

Società	Posizione	Inizio	Fine
The University of Colorado	Corporate Officer/Principal	14/09/2009	-
ApopLogic Pharmaceuticals, Inc. ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO.	Direttore/Membro del Consiglio	01/01/2006	-
	Fondatore	01/01/2006	-

Società	Posizione	Inizio	Fine
GLOBEIMMUNE, INC.	Fondatore	10/02/1995	-
Basel Institute for Immunology	Corporate Officer/Principal	-	-

University of Pennsylvania

Doctorate Degree

Distribuzione geografica

Stati Uniti	5
Svizzera	2

Posizioni

Corporate Officer/Principal	2
Founder	2
Doctorate Degree	1

Settori

Consumer Services	4
Health Technology	3

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
GLOBEIMMUNE, INC.	Health Technology

Aziende private	1
ApopLogic Pharmaceuticals, Inc. ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO.	Health Technology

Aziende private

Health Technology